
Annexon, Inc (ANNX) Stock Forecast & Price Target
Annexon, Inc (ANNX) Analyst Ratings
Bulls say
Annexon is well-positioned to capture a significant portion of the market for C1q inhibitors, with their lead programs showing promising results and a strong executive team in place. However, the company faces competition from other approved drugs and concerns about the effectiveness of their lead program, vonaprument. It will be important for Annexon to continue to demonstrate the efficacy of their drugs for various conditions and successfully navigate the competitive landscape in order to realize their potential and provide value for investors.
Bears say
Annexon is a clinical-stage biopharmaceutical company with a promising pipeline of products targeting the classical complement pathway, a well-studied mechanism in autoimmune and neurodegenerative diseases. However, their lead drug for a potential $3B market has a low chance of success in its Phase 3 trial, and there may be challenges in marketing and reimbursement for their products. As a result, there is a negative outlook on Annexon's stock.
This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.
Annexon, Inc (ANNX) Analyst Forecast & Price Prediction
Start investing in Annexon, Inc (ANNX)
Order type
Buy in
Order amount
Est. shares
0 shares